Compare Charles River Laboratories Intl. Inc (CRL) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs LTC Properties Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $229.26 (market cap $11.14B), while LTC Properties Inc trades at $40.21 (market cap $2.05B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 5.4× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.7% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | LTC | |
|---|---|---|
Market Cap | $11.14B | $2.05B |
Sector | Health | Real Estate |
52-Week High | $233.60 | $40.36 |
52-Week Low | $145.57 | $33.98 |
Enterprise Value | $14.00B | $2.90B |
Dividend Yield | — | 5.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
LTC Properties (LTC) trades at $39.67, up 2.08% today, with a bullish technical signal from moving averages and a P/E of 15.56. Revenue grew to $263M in 2025, with a net income margin of 39.09%, though recent quarters saw earnings misses. The company is expanding its SHOP portfolio, with acquisitions like the $73M purchase in July 2026, and maintains a monthly dividend of $0.19 per share.
Outlook is mixed: strong fundamentals and demographic trends support growth, but earnings volatility and high debt pose risks. Analysts are cautious, with 59% holding neutral ratings. Key catalysts include SHOP transition success, while risks involve interest rate sensitivity and execution challenges in acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
